Nanobodies as probes to investigate purinergic signaling.

Nanobodies as probes to investigate purinergic signaling. Biochem Pharmacol. 2020 Dec 31;:114394 Authors: Eggers M, Rühl F, Haag F, Koch-Nolte F Abstract Nanobodies (VHHs) are the single variable immunoglobulin domains of heavy chain antibodies (hcAbs) that naturally occur in alpacas and other camelids. The two variable domains of conventional antibodies typically interact via a hydrophobic interface. In contrast, the corresponding surface area of nanobodies is hydrophilic, rendering these single immunoglobulin domains highly soluble, robust to harsh environments, and exceptionally easy to format into bispecific reagents. In homage to Geoffrey Burnstock, the pioneer of purinergic signaling, we provide a brief history of nanobody-mediated modulation of purinergic signaling, using our nanobodies targeting P2X7 and the NAD-metabolizing ecto-enzymes CD38 and ARTC2.2 as examples. PMID: 33388283 [PubMed - as supplied by publisher]
Source: Biochemical Pharmacology - Category: Drugs & Pharmacology Authors: Tags: Biochem Pharmacol Source Type: research